Heroin detoxification with buprenorphine on an inpatient psychiatric unit

被引:16
作者
DiPaula, BA
Schwartz, R
Montoya, ID
Barrett, D
Tang, C
机构
[1] Walter P Carter Ctr, Dept Pharm Serv, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[3] Friends Res Inst, Baltimore, MD 21285 USA
[4] NIDA, Div Treatment Res & Dev, Bethesda, MD 20892 USA
[5] Univ Maryland, Sch Med, Walter P Carter Ctr, Baltimore, MD 21201 USA
关键词
buprenorphine; detoxification; heroin dependence; psychiatric comorbidity; psychiatric hospitalization;
D O I
10.1016/S0740-5472(02)00244-1
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The purpose of this open-label, uncontrolled study was to evaluate the feasibility of administering off-label buprenorphine in combination with ancillary medications for inpatient short-term detoxification of heroin-dependent patients at a psychiatric facility. A sample of 20 heroin-dependent patients admitted to an urban psychiatric hospital was administered buprenorphine 6, 4, and 2 mg/day during the first, second, and third day of detoxification, respectively, and then observed during the fourth and fifth day. Eighty-five percent of the subjects abused other substances, 75% reported cocaine abuse/dependence, 75% had comorbid mood disorders. All subjects completed the medication phase of the study. No clinically significant adverse events were reported. There was a significant decrease in the Clinical Investigation Narcotic Assessment (CINA) total score between baseline and days 2 through 5. The results suggest that buprenorphine is well tolerated and may be beneficial for medically supervised short-term withdrawal from heroin for hospitalized psychiatric patients. (C) 2002 Elsevier Science Inc. All fights reserved.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 21 条
[1]   Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet [J].
Amass, L ;
Kamien, JB ;
Mikulich, SK .
DRUG AND ALCOHOL DEPENDENCE, 2000, 58 (1-2) :143-152
[2]  
Blennow G, 2000, Lakartidningen, V97, P1830
[3]  
Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71
[4]   A CONTROLLED COMPARISON OF BUPRENORPHINE AND CLONIDINE FOR ACUTE DETOXIFICATION FROM OPIOIDS [J].
CHESKIN, LJ ;
FUDALA, PJ ;
JOHNSON, RE .
DRUG AND ALCOHOL DEPENDENCE, 1994, 36 (02) :115-121
[5]   Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes [J].
Dixon, L .
SCHIZOPHRENIA RESEARCH, 1999, 35 :S93-S100
[6]  
Dixon L, 1998, AM J PSYCHIAT, V155, P239
[7]   Gender differences in Axis I comorbidity among depressed outpatients [J].
Fava, M ;
Abraham, M ;
Alpert, J ;
Nierenberg, AA ;
Pava, JA ;
Rosenbaum, JF .
JOURNAL OF AFFECTIVE DISORDERS, 1996, 38 (2-3) :129-133
[8]  
GOWING L, 2000, COCHRANE DB SYST REV, V2
[9]  
GOWING L, 2000, COCHRANE DB SYST REV, V3
[10]   Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine [J].
Kuhlman, JJ ;
Lalani, S ;
Magluilo, J ;
Levine, B ;
Darwin, WD ;
Johnson, RE ;
Cone, EJ .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1996, 20 (06) :369-378